ENAVATE SCIENCES GP, LLC
An institutional investment manager in New York, NY. Its Form 13F for the quarter ended Jun 30, 2026, filed Aug 14, 2026. SEC CIK 1953107.
- Reported value$345.4m
- Positions7
Holdings: 7 positions
The filing on sec.govAs filed, largest first. Reported value is what the manager stated for each position at the quarter end, in US dollars; it is filing data, not a price. Weight is the position's share of the total reported value. Changes compare with the 13F for the quarter ended 2026-03-31.
| Issuer | Class | CUSIP | Reported value$m | Weight | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|---|---|
| Sionna Therapeutics IncSION | COM | 829401108 | 109 | 31.6% | 2,478,030 | Unchanged | |
| Zenas Biopharma IncZBIO | COM | 98937L105 | 99.5 | 28.8% | 3,919,159 | Unchanged | |
| Immunome IncIMNM | COM | 45257U108 | 76.6 | 22.2% | 3,613,799 | Unchanged | |
| Bridgebio Oncology TherapeutBBOT | COM NEW | 107924102 | 20.0 | 5.8% | 2,626,946 | Unchanged | |
| Compass Therapeutics IncCMPX | COM | 20454B104 | 17.1 | 4.9% | 7,788,150 | Unchanged | |
| Upstream Bio IncUPB | COM | 91678A107 | 17.0 | 4.9% | 2,459,703 | Unchanged | |
| CAMP4 Therapeutics CorpCAMP | COM | 13463J101 | 6.2 | 1.8% | 1,425,541 | Reduced−765,379 |
Source: SEC EDGAR, Form 13F-HR, accession 0001953107-26-000012 (on sec.gov). Last ingested by Listed: Oct 22, 2026, 05:26 ET. Listed shows no prices and gives no investment advice.